Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data-Reference-Cited by-同舟云学术

Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data

Published:2020-09 Issue: Volume:89 Page:102085
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Passaro Antonio^ORCID,Attili Ilaria,Morganti Stefania,Del Signore Ester,Gianoncelli Letizia,Spitaleri Gianluca,Stati Valeria,Catania Chiara,Curigliano Giuseppe^ORCID,de Marinis Filippo

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference107 articles.

1. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

2. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

3. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

4. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial;West;Lancet Oncol,2019

5. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melatonin reverses EGFR-TKI therapeutic resistance by modulating crosstalk between circadian-related gene signature and immune infiltration patterns in patients with COVID-19 and lung adenocarcinoma;Computers in Biology and Medicine;2024-09

2. Predictive value of inflammation and nutritional index in immunotherapy for stage IV non-small cell lung cancer and model construction;Scientific Reports;2024-07-30

3. Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer;Frontiers in Immunology;2024-06-18

4. Impact of PD-L1 Expression on the Overall Survival of Caucasian Patients with Advanced EGFR-Mutant NSCLC Treated with Frontline Osimertinib;Targeted Oncology;2024-06-03

5. Variation of peripheral blood-based biomarkers for response of anti-PD-1 immunotherapy in non-small-cell lung cancer;Clinical and Translational Oncology;2024-03-07